[#바이오스펙테이터](?q=%23%EB%B0%94%EC%9D%B4%EC%98%A4%EC%8A%A4%ED%8E%99%ED%85%8C%EC%9D%B4%ED%84%B0) [#전일](?q=%23%EC%A0%84%EC%9D%BC)(10/30, FRI) [#전체기사](?q=%23%EC%A0%84%EC%B2%B4%EA%B8%B0%EC%82%AC)

 릴리, '삼중작용제' 첫 직접비교 3상서 "오젬픽 이겨"
[https://www.biospectator.com/news/view/30238](https://www.biospectator.com/news/view/30238)

 대원제약, 'P-CAB' 위식도역류질환 3상 "1차종결점 충족"
[https://www.biospectator.com/news/view/30239](https://www.biospectator.com/news/view/30239)
 
 GC-한미, 바이오마린에 '파브리병 ERT' 4.75억弗 L/O
[https://www.biospectator.com/news/view/30240](https://www.biospectator.com/news/view/30240)

 아스텔라스, 오닥스 'IL-12 타깃’ 약물 13.4억弗 옵션딜
[https://www.biospectator.com/news/view/30231](https://www.biospectator.com/news/view/30231)

 GC녹십자, '헌터라제ICV' 헌터증후군 "식약처 허가"
[https://www.biospectator.com/news/view/30246](https://www.biospectator.com/news/view/30246)

 젠맙, 'EGFRxLGR4' 두경부암 3상 키트루다比 "OS 50%↑"
[https://www.biospectator.com/news/view/30230](https://www.biospectator.com/news/view/30230)

 '키트루다 SC’ 3Q 매출 8.3억弗.."전분기比 79.3%↑"
[https://www.biospectator.com/news/view/30247](https://www.biospectator.com/news/view/30247)

 릴리, 3Q 매출 244억弗..올해 전망치 “100억弗 상향” 
[https://www.biospectator.com/news/view/30241](https://www.biospectator.com/news/view/30241)

 앱클론, 공동개발 'TIGIT 항체' 유한양행에 권리이전
[https://www.biospectator.com/news/view/30249](https://www.biospectator.com/news/view/30249)

 올릭스, '황반변성 RNAi' 호주2a상 "IND 승인"
[https://www.biospectator.com/news/view/30250](https://www.biospectator.com/news/view/30250)

 반다, ‘NK1 길항제’ GLP-1 부작용 3상 “구토 27%↓"
[https://www.biospectator.com/news/view/30243](https://www.biospectator.com/news/view/30243)

 삼성바이오에피스, '키트루다 시밀러' FDA 승인신청
[https://www.biospectator.com/news/view/30251](https://www.biospectator.com/news/view/30251)

 넥스아이, 공모가 8000원 확정 "밴드 하회"
[https://www.biospectator.com/news/view/30252](https://www.biospectator.com/news/view/30252)

[#바이오스펙테이터](?q=%23%EB%B0%94%EC%9D%B4%EC%98%A4%EC%8A%A4%ED%8E%99%ED%85%8C%EC%9D%B4%ED%84%B0) [#전일](?q=%23%EC%A0%84%EC%9D%BC)(10/30, FRI) [#전체기사](?q=%23%EC%A0%84%EC%B2%B4%EA%B8%B0%EC%82%AC)